The product CSB-E07929h is a ready-to-use ELISA kit specifically designed and validated for the quantitative detection of human platelet-activating factor (PAF) in multiple biological solutions, including serum, urine, cell culture supernates, tissue homogenates, or cell lysates. It is not intended for diagnostic use. This assay kit was designed and optimized for biochemical research use in humans. The kit has undergone rigorous quality control in multiple parameters, including sensitivity, specificity, precision, linearity, recovery, and inter-batch difference. Refer to the product instructions for more details.
This assay employs the quantitative sandwich enzyme immunoassay technique, in which PAF in the samples or standards are sandwiched between pre-coated PAF antibody and Biotin-conjugated PAF antibody. HRP-avidin is then added to the wells. Following a wash to remove any unbound reagent, the TMB substrate solution is added to the wells and color develops in proportion to the amount of PAF bound in the initial step. The color development is stopped upon adding the stop solution, and the intensity of the color is measured at 450 nm via a microplate reader. The levels of PAF in the samples can be determined by referring to the O.D. (optical density) of the samples to the standard curve.
PAF is a potent phospholipid mediator originally described by its ability to cause platelet aggregation and dilation of blood vessels. It also potently mediates inflammation, allergic responses, and shock. It causes acute inflammation of the airway leading to asthmalike symptoms. PAF is involved in the development of cancer and other inflammatory conditions such as cardiovascular disease. It exerts a predominant role in angiogenesis, thrombosis, carcinogenesis, and metastasis.